Press

1. IntelliDose Launches IntelliScribe March 2, 2010
2. IntrinsiQ Sharpens Cancer Treatment Analysis February 10, 2010
3. Dayton Physicians Commits to Clinical Excellence by Partnering with IntelliDose February 2, 2010
4. IntelliDose Exhibiting at Fifth Annual Community Oncology Conference February 5–6, 2010
5. New York cancer care center uses automation to handle coding, reimbursement January 29, 2010
6. Tarceva Reprieve? FDA Delay Could Mean Little Either Way January 25, 2010
7. WWMR Vice President Invited to Speak at PBIRG Fall Biotech Workshop December 7, 2009
8. Panel Advises on Clinical Pathways: What, Why, and How November, 2009
9. IntrinsiQ Expands Executive Team November 3, 2009
10. IntelliDose Exhibiting at North Carolina Oncology Management Society 2009 Fall Conference November 18 to 20, 2009
11. Opportunity reconsidered: maintenance therapy in oncology October, 2009
12. IntrinsiQ Study: Oncologists Overlook Maintenance Therapy Option – More Often than They Realize September 15, 2009
13. Industry Thought Leaders: A Discussion with Jeff Forringer, President of IntrinsiQ, LLC August 2009
14. Are CPOEs worth the investment? August 2009
15. Information Technology: Tracking the Evolution of Oncology Drug Prescribing August 2009
16. Rich Gray, General Manager of IntelliDose, to Speak at ACCC 26th National Oncology Economics Conference September 22 to 25, 2009
17. IntelliDose Exhibiting at eClinicalWorks 2009 National Users Conference September 12 to 15, 2009
18. Jeff Forringer, President of IntrinsiQ, to Speak at the Magellan/ICORE 6th Annual Oncology Summit September 11, 2009
19. IntelliDose Exhibiting at GE Centricity User Group Fall Conference August 28 and 29, 2009
20. How Much Should Cancer Drugs Cost: Landmark Cornell University Study Sheds New Light on Old Assumptions August 4, 2009
21. IntrinsiQ Sponsors Cancer Center Business Summit October 8-9, 2009
22. The First Step to a Paperless Practice July 1, 2009
23. On the Move – Spotlight on Jeff Forringer June 19, 2009
24. Specialized chemotherapies increase market share, cost of care June 2009
25. IntrinsiQ Acquires Market Research Firm WWMR June 9, 2009
26. IntrinsiQ Appoints New Executive Team May 12, 2009
27. IntrinsiQ's IntelliDose May 2009
28. The real cost of treating off-label and off-guidelines March 2009
29. NewsMakers March 2009
30. Small mistakes, huge consequences; Onc-specific software improves safety February 2009
31. Safe Handling; The Right Drug, Right Dose, Right Patient January/February 2009
32. Automated Oncology February 2009
33. Still Using Paper and Pen? January 2009
34. OnCare Hawaii Selects IntelliDose for Oncology Patient Safety and Practice Efficiency January 6, 2009
35. Safe Handling December 2008
36. Market Opportunity in Lung Cancer December 2008
37. Cancer Center of South Florida Selects IntelliDose for All-Electronic Practice November 3, 2008
38. IntrinsiQ Launches IntelliDose 3.8 October 27, 2008
39. Technology: Can Oncology EMRs Improve Quality? September 2008
40. IntrinsiQ Builds Out Its Oncology-Products Market Analytics September 2008
41. IntrinsiQ Wins 3 Top Honors from Inc. Magazine September 9, 2008
42. New Reporting from IntrinsiQ Measures Impact of Key Events on Oncology Drug Usage September 2, 2008
43. High Drug Costs a Factor in Cancer Care August 28, 2008
44. Pharmawire analysis: Cyclacel's seliciclib comes under physician scrutiny August 2008
45. DSS Licenses IntelliDose to Standardize VA Oncology Practices August 18, 2008
46. Buried Treasure June 23, 2008
47. Data from the Doctor April 15, 2008
48. IntrinsiQ LLC - Dose of Success March 7, 2008
49. IntelliCost Provides Cost of Therapy Insight for Sizing New Market Opportunities February 13, 2008
50. Software application aims to eliminate human error in chemotherapy dosing January 11, 2008
51. Oncologists Nationwide Choose IntelliDose for Clinical Safety and Efficiency November 28, 2007
52. IntrinsiQ Expands Oncology’s Gold-Standard for Patient Data Collection September 25, 2007
53. IntelliDose to Participate in ASCO EHR Symposium July 19, 2007
54. GE Healthcare and IntrinsiQ Announce Collaboration to Link Clinical Oncology Information within Patient Electronic Medical Records May 31, 2007
55. IntelliDose® Unveils IntelliCharge — Automated Encounter Charge Capture Improves Control and Billing of Costly Chemotherapy Drugs May 31, 2007
56. PRA International and IntrinsiQ Research Enter Exclusive Agreement for Oncology Patient Treatment Data March 19, 2007
57. Pulse and IntrinsiQ Sign Strategic Agreement January 16, 2007
58. IMS, IntrinsiQ Research Establish Strategic Alliance to Deliver Global, Clinically Rich Oncology Market Intelligence August 2, 2006
59. Accel-KKR Acquires Majority Stake in IntrinsiQ June 20, 2006

IntrinsiQ Appoints New Executive Team

Healthcare, Pharmaceutical and Data Industry Veterans Extend Cancer Care Experts' Depth and Reach

Waltham, Mass. (May 12, 2009) — A new leadership team at IntrinsiQ today initiates a singular mission: to improve the quality of cancer care, by giving every stakeholder in the oncology field – physicians, nurses, pharmacists, practice managers, pharmaceutical researchers and managed care professionals – more clarity and insight into the clinical care process.

Led by Jeff Forringer, who becomes president after six years of successfully growing IntrinsiQ's pharmaceutical oncology consulting practice, IntrinsiQ's executive team now includes Rich Gray as division general manager of the IntelliDose® clinical software division, Mike Raquet as division general manager of the pharmaceutical data division, Steve Hamann as vice president of technology and Rob Weisman as director of finance.

To achieve this vision, the executive team will invest in new delivery models to increase the ease of deployment and accelerate practice-wide adoption of IntelliDose's full functionality. It will also give:

• Deep and actionable insight for oncology practices into treatment decisions and clinical best-practices, as well as opportunities to improve workflow and profitability. The team will also continue to partner and interoperate with leading electronic medical record (EMR) providers to become the medical oncology module of choice.

• Custom analysis of emerging clinical care trends for pharmaceutical clients to accurately interpret market factors that drive doctors' decisions, like statistically significant clinical research findings or removing reimbursement obstacles.

"Our goal is to give patients the best chance of beating the odds," said Forringer. "That's what happens when doctors make optimal treatment decisions, nurses correctly administer chemotherapy treatments and get more time to listen, and researchers bring to market new therapies and combinations that allow more patients to be treated – with better outcomes."

IntrinsiQ is considered oncology's leading source of real-time, real-world data for cancer treatment. Its analysis of 2 million drug administrations from more than 500 oncologists collected in IntelliDose each year helps everyone in the care spectrum identify the most effective treatments and emerging best practices.

Oncology Market Veterans to Lead Growth

Forringer's promotion to president culminates a 20-year career of building pharmaceutical information partnerships. One of the earliest members of the IntrinsiQ team, he grew IntrinsiQ's pharmaceutical data practice into researchers' go-to resource. Today, 28 of the top 30 global pharmaceutical companies are IntrinsiQ clients.

Gray returns to IntrinsiQ to lead the IntelliDose clinical software division. He brings more than 25 years of healthcare information technology experience working with companies like Meditech and MSM, Inc. Gray will tap his deep clinical experience as a registered pharmacist to manage sales, marketing, product management, and customer satisfaction teams.

Raquet spearheads pharmaceutical client service efforts to further the knowledge and understanding of oncology treatment. He brings 25 years of experience in every aspect of the pharmaceutical industry including clinical research, marketing, sales and manufacturing from senior-level positions at IMS Health, PRA International, and Tunnell Consulting.

Hamann is promoted to the management team following two years of spearheading a strategic roadmap to improve the user interface and underlying architecture of IntelliDose.

Weisman is promoted to director of finance after serving as IntrinsiQ's controller for two years. In previous positions, he served as controller at Sports Loyalty Systems and ISI Emerging Markets.

Gray, Raquet, Hamann and Weisman report to Forringer.

About IntrinsiQ

IntrinsiQ, LLC is the leading provider of medical oncology clinical information systems and the premier source of US oncology data and analysis. Each month, IntrinsiQ’s clinical software application, IntelliDose®, captures the treatment decisions and details from more than 500 oncologists, for nearly 20,000 unique patients, creating a database unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. This database is the foundation of products and services that uniquely address the business information needs of pharmaceutical product managers, market researchers and financial analysts. For more information, please visit www.intrinsiq.com.

IntrinsiQ Company Contact:

Diane Poth
(781) 434-3304
diane.poth@intrinsiq.com

IntrinsiQ Media Contact:

Lesley Cannata
(617) 969-9192
lcannata@corporateink.com

© 2010 IntrinsiQ, LLC